DQ-2511) improves experimentally-induced delays in gastric emptying without affecting gastric acid secretion or gastric mucosal blood flow (1-3) and also enhances gastric motility (3). Electro physiological approaches revealed that the drug elicited a facilitatory effect on the gastric efferent activity as a result of a disinhibitory reflex action originating from sup pressed gastric afferents (4) . Although the binding affinity of ecabapide to selective receptors has been exhaustively explored, it showed no specific binding (2, 5) . On the ba sis of the above studies, ecabapide was considered to exert its action via suppression of activation of afferents in the sensory component of gastric inhibitory vago-vagal reflex pathways (3, 4) . More recently, ecabapide was reported to stimulate the intracellular production of guanosine 3",5' cyclic monophosphate (cGMP) content (5, 6 ) at a con centration as low as 10-' M when rabbit gastric parietal cells were used (7) . To date, stimulation of guanylate cy clase and accumulation of intracellular cGMP have been proposed to induce smooth muscle relaxation related to nitric oxide (NO), which plays a pivotal role as a key mediator in these events (8, 9) . In the present communi cation, to elucidate the possible role of NO in the sup pression of gastric vagal afferents due to ecabapide, we examined the effect of either an NO donor sodium nitroprusside (SNP) or the NO biosynthesis inhibitor N' nitro-L-arginine (L-NNA) on the afferent discharge rate in anesthetized rats using a standard extracellular method of multi-unit recording (10) . Furthermore, we assessed the effect of pretreatment with L-NNA on the suppression of gastric vagal afferents due to ecabapide and then esti mated the effect of changes in gastric motility on afferent discharges using atropine, a competitive antagonist of muscarinic cholinoceptors.
Eight to nine-week-old male Wistar rats weighing 250 to 350 g were used for the investigation. The animals were fasted overnight but allowed free access to water until the beginning of the experiments. Ecabapide was synthesized at our laboratory. SNP and L-NNA were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and atro pine supplied from Tanabe Co. (Osaka). Ecabapide (60 pg/kg), SNP (0.5 mg/kg), L-NNA (5 mg/kg) and atro pine (0.05 mg/kg) were dissolved in or diluted with sterile 0.9010 saline solution and injected into the abdominal vein at a constant volume of 0.6 ml/kg. In an additional study using the same dose, L-NNA was administered to rats 1 hr prior to ecabapide treatment. The dosage level of each agent used in the present investigation was selected on the basis of preliminary studies or previously published reports (3, 4, 11, 12) . Multi-unit neural discharge in the vagal afferent fibers was recorded extracellularly. Stan dard methods of extracellular recording from vagal nerve filaments were used, as described in detail elsewhere (10) . In brief, rats were anesthetized with urethane (1 g/kg, i.p.), and the body temperature was maintained with a 371C heating pad throughout the experiment. The nerve filaments were dissected from the distal cut end of the ventral gastric branch of the vagus nerve to record the multi-unit vagal afferent activity originating from the stomach that was measured with a pair of silver wire electrodes. Nerve activity was amplified by a condenser coupled differential amplifier (DPA-100E; Dia Medical Systems Co., Tokyo), displayed on an oscilloscope and stored on a magnetic tape. All analyses of nerve activity were performed after the conversion of raw data to stan dard pulses by use of a window discriminator (DSE 325A, Dia Medical Systems), which distinguished nerve activity from background noise. For the calculation of the discharges, a rate meter with a reset time of 5 sec was used to observe the time course of the nerve activity, which was recorded with a pen recorder (8K20; NEC-San Ei Co., Tokyo). The action of each agent was examined by comparing the mean number of impulses per 5 sec over 50 sec (i.e., the mean value of ten successive measured samples) before and after treatment. The results are ex pressed as the mean±S.E.M.
Quantitative data were tested by one-way analysis of variance or the Dunnett type multiple comparison test. A P value of less than 0.05 was regarded as significant. SNP (0.5 mg/kg) depressed the afferent discharge rate of the gastric vagus nerve 30 and 60 min after treatment (Fig. 1, left) , like ecabapide (3, 4) . In contrast, L-NNA (5 mg/kg) significantly elevated its discharge rate 60 min following injection (Fig. 1, right) . This implies that the proposed mechanism underlying the suppression of vagal afferent discharges due to ecabapide may resemble that induced by SNP in response to the NO-cGMP cascade, because ecabapide was found to stimulate cGMP produc tions at 10-' M (7), which almost corresponded to the se rum concentration after i.v. injection of 60 pg/kg. This concentration (10-' M) of ecabapide, however, caused neither relaxation nor contraction of the smooth muscle in rat arteries (5) . Pretreatment with L-NNA completely blocked the action of ecabapide (Fig. 2: A-C) , suggest ing that the depressed afferent discharges provoked by ecabapide may be closely related to NO release. Atropine (0.05 mg/kg) showed no effect on the afferent firing under these experimental protocols (data no shown). The find ing indicates that smooth muscle relaxation itself is not associated with the depression of gastric vagal afferents. Recently, Forster and Southam (13) have stated that the intrinsic and vagal extrinsic innervation of the rat stomach contain NO synthase. In addition, inhibition of NO synthase was reported to cause delays in gastric em ptying (14, 15) . In other words, it is proposed that NO may facilitate gastric emptying. Taken together with our cumulative studies, the results provide supporting evi dence that the NO-cGMP cascade, at least in part, is in volved in the mechanism of action of ecabapide. This speculation may be supported by the fact that 8-Br cGMP, a cGMP analog, elicits the suppression of gastric afferent activity in this test system (S. Hatanaka et al., unpublished data).
In conclusion, ecabapide may suppress activation of gastric vagal afferents through the NO-cGMP cascade, and this phenomenon may be brought about by the action of the drug on the gastric innervation.
